212Pb-LNC1011

N/A

Report date: 2025/11/20 16:04:44

NME

Base Information

Drug Name212Pb-LNC1011

Drug Alias Name212Pb-LNC1011212Pb-LNC-1011

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lead > 212PbRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesYantai Lannacheng Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesYantai Lannacheng Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A